Just found this on line regarding treatment of moderate to severe Covid ARDS with steroids"With a press releaseon June 16, 2020, reporting the results of the UK-based RECOVERY trial, theexisting approach for treating and studying patients with COVID-19 underwent amajor change. In this large open-label randomized trial enrolling 6425 patients(2104 randomized to receive dexamethasone and 4321 randomized to receive usualcare), treatment with dexamethasone (6 mg/d for 10 days) reduced mortality byone-third in patients receiving mechanical ventilation (29.3% vs 41.4%,respectively; rate ratio, 0.64 [95% CI, 0.51-0.81]) and by one-fifth inpatients receiving supplemental oxygen (23.3% vs 26.2%, respectively; 0.82 [95%CI, 0.72-0.94]) compared with usual care alone"
In interested in feedback from learned posters as to our Covid ARDS trial Primary End Pint of all cause mortality at 30 days?
Fred Grossmann has consistently referred to ventilator mortality of 60%
- Forums
- ASX - By Stock
- MSB
- MSB to dispute FDA finding in Type A meeting
MSB to dispute FDA finding in Type A meeting, page-435
-
- There are more pages in this discussion • 583 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B |
Open | High | Low | Value | Volume |
$1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | $1.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.19 | 75212 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 1.185 |
1 | 20000 | 1.175 |
1 | 5664 | 1.170 |
1 | 17568 | 1.160 |
3 | 56695 | 1.150 |
Price($) | Vol. | No. |
---|---|---|
1.190 | 59712 | 2 |
1.195 | 36255 | 5 |
1.200 | 404381 | 31 |
1.205 | 3000 | 1 |
1.210 | 162475 | 7 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |